Welcome to our dedicated page for MetLife SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MetLife’s balance sheet stewards more than half a trillion dollars in insurance reserves and invested assets—numbers that translate into multi-layered disclosures spanning hundreds of pages. Finding where management explains reserve adequacy or how separate-account assets back variable annuity guarantees can feel daunting.
Stock Titan solves that problem. Our AI engine converts each MetLife annual report 10-K into an easy synopsis, highlights key shifts in credit‐quality of the investment portfolio, and flags loss-ratio trends inside every MetLife quarterly earnings report 10-Q filing. Need rapid context on a dividend declaration or reinsurance treaty? The moment a MetLife 8-K material events filing arrives in EDGAR, we post it with an “8-K material events explained” note. Real-time alerts also cover
- MetLife Form 4 insider transactions real-time
- MetLife proxy statement executive compensation
- MetLife executive stock transactions Form 4
Whether you’re comparing segment profit drivers or monitoring statutory capital, our platform keeps every document at your fingertips: MetLife insider trading Form 4 transactions, MetLife annual report 10-K simplified, MetLife SEC filings explained simply, and MetLife earnings report filing analysis. Stop combing through actuarial footnotes; understanding MetLife SEC documents with AI means you save hours and surface insights faster than ever.
MetLife has filed a Form 144 notice for the proposed sale of 1,024 shares of common stock with an aggregate market value of $81,879.04. The sale is planned to be executed through Goldman Sachs on the NYSE, with an approximate sale date of June 27, 2025.
The securities to be sold were acquired in three separate purchases during 2013:
- 31 shares from Deutsche Bank on January 31, 2013
- 902 shares from Goldman Sachs on March 13, 2013
- 91 shares from Goldman Sachs on May 15, 2013
Recent trading activity shows that related entities have sold 1,256 shares in the past three months, totaling approximately $99,076.70 in gross proceeds. The filing was made by the MetLife 401(k) Plan Trust, which maintains an affiliate discretionary manager relationship with the issuer. The company has 671,297,826 shares outstanding.
MetLife has filed a Form 144/A notice for the proposed sale of securities, detailing planned transactions of 547 shares of common stock with an aggregate market value of $42,966.85 through Barclays Capital on the NYSE, scheduled for June 20, 2025.
The securities to be sold were originally acquired in two separate purchases from Deutsche Bank:
- 272 shares acquired on September 20, 2013
- 275 shares acquired on March 21, 2014
Recent trading activity in the past 3 months includes sales by various MetLife accounts totaling 686 shares with combined gross proceeds of $55,391.75. The largest transaction was by the MetLife 401k Plan Trust-Large Cap Equity Index, selling 335 shares for $27,590.60 on March 21, 2025. The company has approximately 671.3 million shares outstanding.
MetLife, Inc. (MET) has filed a Form 144 with the U.S. Securities and Exchange Commission disclosing a planned sale of 27 shares of its common stock. The shares, carrying an aggregate market value of $2,120.85, are slated for sale on or about 20 June 2025 through Barclays Capital, 745 Seventh Ave, New York, NY 10019. The notice cites 671,297,826 shares outstanding, making the proposed transaction an immaterial fraction of total equity.
The filer also reported prior dispositions over the past three months totaling 686 shares for gross proceeds of roughly $55,392, executed on 21 March 2025 and 13 June 2025 by various MetLife-related accounts. The signing party affirms that no undisclosed material adverse information exists and that Rule 10b5-1 representations are satisfied.
MetLife, Inc. (MET) filed a Form 144 with the SEC disclosing a proposed sale of 360 common shares through Barclays Capital on or after 20 June 2025. The shares have an aggregate market value of $28,278, compared with the company’s 671,297,826 shares outstanding, representing less than 0.0001 % of total equity—an immaterial amount from an ownership-dilution perspective.
The filer originally acquired the shares on 29 May 2015 via a purchase from Goldman Sachs for cash. The notice affirms the seller’s representation that no undisclosed material adverse information is known.
Recent trading history: in the last three months, related MetLife accounts collectively sold 686 shares for $55,391.75 in gross proceeds. These transactions, combined with the planned 360-share disposition, remain de minimis relative to MetLife’s market capitalization and average daily trading volume. No financial performance data, strategic updates or governance changes accompany the filing.
Given the modest size and routine nature of the transaction, the filing is unlikely to influence MetLife’s valuation or trading dynamics.
FAQ
What is the current stock price of MetLife (MET)?
What is the market cap of MetLife (MET)?
